新闻BenzingaReported Earlier, AstraZeneca’s Alexion Wins US Accelerated Approval For Ultomiris As First C5 Inhibitor To Reduce Proteinuria In IgA Nephropathy Adults; Phase III I CAN Shows 43.4% Reduction Versus Placebo At 34 Weeks Reported Earlier, AstraZeneca’s Alexion Wins US Accelerated Approval For Ultomiris As First C5 Inhibitor To Reduce Proteinuria In IgA Nephropathy Adults; Phase III I CAN Shows 43.4% Reduction Versus Placebo At 34 Weeks Benzinga 2026.10.22 06:49 (GMT+0) 在Benzinga上打开 其他新闻 Susquehanna维持对联合航空控股的积极评级，将目标价下调至130美元 Susquehanna维持对Meta Platforms的积极评级，将目标价上调至850美元 Alpha Tau Medical 与首尔三星医疗中心签署谅解备忘录，探讨胰腺癌患者潜在临床研究 Susquehanna维持IBM中性评级，将目标价上调至256美元 Susquehanna维持对Genpact的中性评级，将目标价上调至40美元 Keybanc维持对Meta Platforms的增持评级，将目标价上调至905美元
